Difference between revisions of "Part:BBa K4165156"
Line 8: Line 8:
  
 
The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. MM2 can reduce tau aggregates of full-length tau aggregates but not PHF* or PHF (VQIINK and VQIVYK respectively).
 
The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. MM2 can reduce tau aggregates of full-length tau aggregates but not PHF* or PHF (VQIINK and VQIVYK respectively).
 +
  
 
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>

Revision as of 14:54, 11 October 2022


MM2 Peptide

A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.

Usage and Biology

The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. MM2 can reduce tau aggregates of full-length tau aggregates but not PHF* or PHF (VQIINK and VQIVYK respectively).


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

MM2 is modeled by AlphaFold2, ITASSER and TrRosetta, best model obtained from TrRosetta. 


                            Figure 1.: Predicted 3D structure of Synthetic peptide MM2.


Table 1: Quality assessment parameters of MM2 model.

References

1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany).